# A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia

> **NCT01276353** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 45 (actual)

## Conditions studied

- Alzheimer's Type Dementia

## Interventions

- **DRUG:** E2020
- **DRUG:** E2020

## Key facts

- **NCT ID:** NCT01276353
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276353, "A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01276353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*